Search Results
Your search for The matches 34670 pages
Showing 24001 - 24050ASCO 2016: Precision Medicine Approach May Expand Therapeutic Options for Patients
Researchers reported encouraging early results from a phase II trial that matches patients with molecular abnormalities in the tumor to corresponding targeted treatments. Twenty-nine of 129 patients with 12 different types of advanced cancers responded to drugs outside of U.S. Food and Drug...
ASCO 2016: Chemotherapy Improves Outcomes for Certain Patients With Anaplastic Glioma
For a more in-depth look at these data, please click here. Patients with anaplastic glioma without 1p/19q codeletion benefit from adjuvant chemotherapy, according to early results from a European phase III trial. The estimated 5-year survival rates were 56% with radiation therapy and...
ASCO 2016: Adding Capecitabine Chemotherapy to Gemcitabine Extends Survival After Pancreatic Cancer Surgery
For a more in-depth look at these data, as well as commentary, click here. A European phase III trial, one of the largest ever conducted in pancreatic cancer, showed that adding the oral drug capecitabine chemotherapy to gemcitabine prolongs survival without increased toxicity. Adjuvant...
ASCO 2016: Biosimilar Shows Comparable Efficacy and Safety to Trastuzumab in HER2-Positive Metastatic Breast Cancer
A biosimilar trastuzumab antibody (MYL-1401O) is comparable in efficacy and safety to trastuzumab (Herceptin) in women with HER2-positive advanced breast cancer, according to a randomized phase III study. The response rates were comparable among women who received trastuzumab and among...
ASCO 2016: Adding Intraperitoneal Chemotherapy to Intravenous Chemotherapy Slows Ovarian Cancer Progression
For some women with advanced ovarian cancer that was successfully treated surgically, delivering chemotherapy intraperitoneally as well as intravenously appears more effective than intravenous chemotherapy alone. For women who were initially treated with chemotherapy prior to surgery, the ...
Statement from FDA Commissioner Robert Califf, MD, on the Release of the Final Individual Patient Expanded Access Form
“Today, the U.S. Food and Drug Administration (FDA) finalized its efforts to streamline the process used by physicians to request expanded access, often called ‘compassionate use,’ to investigational drugs and biologics for their patients. As a physician, I understand the...
Poorer Adherence to Endocrine Treatment Associated With Poorer Outcome in Postmenopausal Hormone Receptor–Positive Breast Cancer
In an analysis of the Breast International Group (BIG) 1-98 trial reported in the Journal of Clinical Oncology, Chirgwin et al found that poorer adherence to endocrine therapy was associated with poorer disease-free survival in postmenopausal women with hormone receptor–positive breast cancer ...
5-Year Results of DASISION Trial of Dasatinib vs Imatinib in CML
As reported in the Journal of Clinical Oncology by Cortes et al, the final 5-year results of the DASISION trial support the safety and efficacy of dasatinib (Sprycel) as first-line treatment in patients with chronic myeloid leukemia (CML) in chronic phase. Initial results in the trial led to...
FDA Approves EGFR Mutation–Detecting Blood Test for Non–Small Cell Lung Cancer
The U.S. Food and Drug Administration (FDA) today approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the epidermal growth factor receptor (EGFR) inhibitor erlotinib (Tarceva). This is the first FDA-approved, blood-based genetic test that can detect EGFR gene mutations...
FDA Approves New Diagnostic Imaging Agent to Detect Rare Neuroendocrine Tumors
The U.S. Food and Drug Administration (FDA) today approved Netspot, the first kit for the preparation of Ga-68 dotatate injection, a radioactive diagnostic agent for positron-emission tomography (PET) imaging. This radioactive probe will help locate tumors in adult and pediatric patients with...
Retroviral Replicating Vector That Delivers Cytosine Deaminase to Cancer Cells Active in Recurrent Glioblastoma
A phase I study by Cloughesy et al published in Science Translational Medicine investigating the effectiveness of vocimagene amiretrorepvec (Toca 511), an experimental nonlytic, retroviral replicating vector that delivers cytosine deaminase to cancer cells, and an investigational...
Nearly 20% of Patients With Ovarian Cancer Do Not Undergo Surgery
Nearly 20% of women with ovarian cancer do not undergo surgery, despite it being a standard part of treatment recommendations, according to new research from the Perelman School of Medicine at the University of Pennsylvania. The findings, which suggest that women may live four times longer with...
ASCO Guideline on Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer
As reported by Hope S. Rugo, MD, of the University of California San Francisco Comprehensive Cancer Center, and colleagues in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline on endocrine therapy for hormone receptor–positive metastatic breast cancer. The...
Study Finds Adding Adjuvant Oxaliplatin to Fluoropyrimidine of Benefit in Deficient Mismatch Repair Colon Cancer
In a French retrospective study reported in the Journal of the National Cancer Institute, Tougeron et al found that the addition of adjuvant oxaliplatin to fluoropyrimidine treatment improved disease-free survival in patients with stage III deficient mismatch repair colon cancer. Study Details...
Vulnerable Hospitals, Cancer Surgery Readmissions, and Penalizing Payment Programs
Readmission rates after complex cancer operations tend to be higher in hospitals that are considered to be vulnerable because they serve as safety nets in their communities or have a high number of Medicaid patients. Reasons for higher readmission rates are highly complex and involve socioeconomic...
Survival Benefit Reported With Radiotherapy vs Surgery Alone in Retroperitoneal Sarcoma
In a study using National Cancer Data Base data reported in The Lancet Oncology, Nussbaum et al found that preoperative and postoperative radiotherapy improved overall survival vs surgery alone in patients with retroperitoneal sarcoma. Study Details The study consisted of case-control, propensity ...
ASCO Value Framework Update: A Statement by Julie M. Vose, MD, MBA, FASCO
ASCO today published an updated framework for assessing the relative value of cancer therapies that have been compared in clinical trials. The framework, published by Schnipper et al in the Journal of Clinical Oncology, defines value as a combination of clinical benefit, side effects, and...
FDA Approves New Diagnostic Imaging Agent to Detect Recurrent Prostate Cancer
On May 27, the U.S. Food and Drug Administration (FDA) approved fluciclovine F-18 (Axumin), a radioactive diagnostic agent for injection. Fluciclovine F-18 is indicated for positron-emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated...
Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States
A model developed to estimate the absolute risk of breast cancer suggests that a 30-year-old white woman in the United States has an 11.3% risk, on average, of developing invasive breast cancer by the age of 80, according to a new study published by Maas et al in JAMA Oncology. Breast cancer is a...
International Prognostic Index for Patients With Chronic Lymphocytic Leukemia
The International Chronic Lymphocytic Leukemia–International Prognostic Index (CLL-IPI) working group has developed an IPI for patients with chronic lymphocytic leukemia based on a meta-analysis of individual patient data, as reported in The Lancet Oncology. Study Details The meta-analysis...
Early Lapatinib-Related Rash Associated With Improved Outcome in Breast Cancer
An analysis of the phase III adjuvant ALTTO trial showed that early rash was associated with better clinical outcome with lapatinib (Tykerb) treatment of HER2-positive breast cancer, as reported by Sonnenblick et al in the Journal of the National Cancer Institute. It had been previously found that...
Women With New-Onset Atrial Fibrillation May Be at Increased Risk for Malignant Cancer
Among nearly 35,000 initially healthy women who were followed for about 20 years, those with new-onset atrial fibrillation had an increased risk of cancer, according to a study published by Conen et al in JAMA Cardiology. Atrial fibrillation, the most common cardiac arrhythmia, is associated with...
QOPI-Certified Practices Eligible to Receive Discount on Medical Malpractice Rates
ASCO and its wholly owned subsidiary, Quality Oncology Practice Initiative (QOPI®) Certification Program, LLC (QCP), announced May 25 that The Doctors Company, the nation's largest physician-owned medical malpractice insurer, will recognize QOPI® Certification in its rate structure....
DDW 2016: Rates of Colorectal Cancer Continue to Increase in Those Under 50
A new study shows the rate of colorectal cancer continues to increase in individuals under 50 years old, despite the fact that the overall rate of the disease has been declining in recent years. Following examination of more than 1 million colorectal cancer patient records over 10 years,...
DDW 2016: Low-Residue Diet Prior to Colonoscopy Shows Improved Tolerance and Bowel Preparation vs Clear Liquid Diet
A new study finds that patients who ate certain solid foods, considered “low residue,” were better prepared for their colonoscopies than individuals who followed the conventional liquid diet. Additionally, researchers saw that these patients who ate foods such as eggs, white bread,...
DDW 2016: Racial Disparities Found in Liver Cancer Survival Rates
Black patients diagnosed with hepatocellular carcinoma, the most common liver cancer, had a 33% increased risk of death compared to non-Hispanic whites. They also were far less likely to receive lifesaving liver transplants, according to a new study presented by Jones et al at Digestive Disease...
DDW 2016: Endoscopist’s Knowledge of Positive Cologuard Test Improves Colonoscopy Performance
An endoscopist's knowledge of a positive Cologuard test improves colonoscopy performance, according to a poster presentation by Johnson et al at Digestive Disease Week (DDW) 2016 (Abstract Su1044). Cologuard is an at-home, stool-DNA colorectal cancer screening test that has been approved by the...
New ASCO Cervical Cancer Guidelines Address Global Resource Disparities
On May 25, ASCO issued its first clinical practice guideline on invasive cervical cancer. This resource-stratified guideline is the first of its kind from ASCO, offering treatment recommendations tailored to resource availability. Access to cervical cancer care varies between regions of the...
External Validation of a Prediction Tool for Chemotherapy Toxicity in Older Patients With Cancer
Hurria et al validated a prediction tool for chemotherapy toxicity in cancer patients aged ≥ 65 years in an external cohort, according to a report in the Journal of Clinical Oncology. The predictive model had been developed in a prior study in 500 patients. Study Details The study...
Play-Based Procedural Preparation May Aid Children Undergoing Cranial Radiation Therapy
Play-based procedural preparation not only helps children cope with the stress and anxiety of radiation therapy, but can also help reduce the amount of sedation used and cut costs, according to a study from the Child Life Program at St. Jude Children’s Research Hospital. The study was...
Leisure-Time Physical Activity Reduces Risk of Multiple Cancer Types
In a study reported in JAMA Internal Medicine, Moore et al found that greater leisure-time physical activity was associated with a reduced risk for many types of cancer. Study Details The study used pooled data on 1.44 million adults from 12 prospective U.S. and European cohorts with...
Colleagues Tip Their Hats to Allen S. Lichter, MD, FASCO
After serving as ASCO’s CEO for 10 years, Allen S. Lichter, MD, FASCO, is stepping down. Dr. Lichter, who has been an ASCO member since 1980, has served the Society in numerous capacities. Along with his distinguished career at ASCO, Dr. Lichter is a nationally recognized radiation oncologist,...
2016 Oncology Meetings
MAY Lymphoma: State-of-the-Art in Biology Therapy, and Patient CareMay 13-14 • New York, New YorkFor more information: msklymphoma2016.com NCI “Sandpit” on Individual and Contextual Factors of Population-Level Cancer ControlMay 16-18 • Montgomery County, MarylandFor more...
Surgical Oncologist Suzanne L. Topalian, MD, Shines at the Forefront of Groundbreaking Research in Cancer Immunotherapy
Nationally recognized surgical oncologist and researcher Suzanne L. Topalian, MD, had an early interest in the arts as well as science and decided to major in English upon entering Wellesley College in Wellesley, Massachusetts. “I wanted to keep all my options open, so I also enrolled in a pre-med...
Noted Gastrointestinal Oncologist Leonard Saltz, MD, Tempers Optimism With Reality and Factors Cost Into the Equation of Value in Cancer Care
Leonard Saltz, MD, was born in New York, New York, and reared in Westchester County, in the suburbs of the City. Terrance Archer, his high-school biology teacher, whom Dr. Saltz described as a “force of nature,” a wonderful human being, and a major role model, influenced his nascent curiosity in...
In Memoriam
The ASCO Post remembers the following specialists in oncology who passed away in 2015–2016. Please write to editor@ASCOPost.com to recognize and pay tribute to others in a future issue. Mark R. Green, MD January 3, 1945–February 23, 2015 “Few people have impacted cancer clinical research in the...
Recipients of the David A. Karnofsky Memorial Award and Lecture
David A. Karnofsky, MD, dedicated himself to the pursuit of scientific excellence and the investigation of more effective therapies for cancer for nearly 30 years, from the time he was a resident at the Collis P. Huntington Memorial Hospital for Cancer Research of Harvard University, until his...
Physician-Researcher Carolyn Jean Presley, MD, Envisions Enhancing Geriatric Oncology
Carolyn Jean Presley, MD, a Robert Wood Johnson Foundation clinical scholar in medical oncology at the Yale Cancer Center, was born in Duluth, Minnesota, which hugs the north shore of Lake Superior, making it one of the nation’s coldest cities during its long winters. She grew up the middle child...
Lisa A. Newman, MD, MPH, FACS, FASCO, Balances Her Passions of Surgical Breast Oncology and Breast Cancer Disparity Research, Both Home and Abroad
Lisa A. Newman, MD, MPH, FACS, FASCO, Director of the Henry Ford Health System’s Breast Oncology Program, was born in New York, New York and, according to her, was blessed to have had parents who lived the African American version of the “American Dream.” Dr. Newman’s father was the son of...
A Pioneer in Lung Cancer Research, James L. Mulshine, MD, Champions Early Population-Based Lung Cancer Screening
A neighborhood doctor who told a good story was an unwitting mentor to internationally regarded lung cancer expert James L. Mulshine, MD. Born in Elizabeth, New Jersey, Dr. Mulshine relocated with his family to West Hartford, Connecticut, when he was a year old, and except for a brief hiatus on...
With a Strong Personal Connection to His Patients, Stephen P. Hunger, MD, Strives for a Cure for All Children With Leukemia
Nationally regarded children’s cancer specialist Stephen P. Hunger, MD, was born and reared in South Windsor, a small suburb of Hartford, Connecticut. Dr. Hunger grew up in the mid-1960s and 1970s, and in his words, “South Windsor was a pretty homogeneous experience. There wasn’t really any ethnic...
International Authority on Radiation Effects, Robert Peter Gale, MD, PhD, Has Pushed Scientific Boundaries in Search of Answers
It is widely reported that the first use of sargramostim (Leukine) in humans (granulocyte macrophage colony-stimulating factor; GM-CSF) was to treat victims of the Goiânia, Brazil, radiation accident in 1987. However, recently declassified documents show that sargramostim was first used a year...
About the Contributors
Ronald Piana is an independent writer and reporter with more than 20 years of experience in oncology communications and publishing. In addition to the profiles published in this special supplemental issue of The ASCO Post, Ron has written more than 100 news and feature articles, interviews, and...
Once a Vocational Nomad, Christine H. Chung, MD, Now Works to Promote Patient-Centered Care in Head and Neck Cancer
Christine H. Chung, MD, Chair of the Department of Head and Neck-Endocrine Oncology at Moffitt Cancer Center, Tampa, Florida, was born and reared in Seoul, Republic of Korea. Dr. Chung immigrated with her mother and two brothers to Los Angeles, where her family then resided. Dr. Chung did not speak ...
Celebrating ASCO 2016 Awards Recipients
Peter Paul Yu, MD, FACP, FASCO, Immediate Past President of ASCO and Chair of the Special Awards Selection Committee, announced the recipients of this year’s special awards. “The exceptional accomplishments of each of our awardees reflect their exemplary dedication to furthering cancer research and ...
With an Illustrious Career in Breast Oncology, Daniel F. Hayes, MD, FASCO, Follows in the Footsteps of Giants as ASCO President-Elect
ASCO President-Elect Daniel F. Hayes, MD, FASCO, was born in Shelbyville, Indiana, a small city in the center of the state. “My dream was to become a high school basketball and track and field coach; my older brother wanted to be a doctor, and his ambitions also began in first grade,” revealed Dr....
Allen S. Lichter, MD, FASCO, Reflects on His Career Path and His Tenure as ASCO CEO, and Predicts a Bright Future for Radiation Oncology
Choosing a career path is one of life’s most challenging decisions, but for Allen S. Lichter, MD, FASCO, deciding to become a doctor was inherently natural. He was born with a great mentor and role model: his father. “I was born and raised in Detroit. My father was a general practitioner in...
Monitoring Survivors of Childhood Cancers for Late Effects of Treatment
This past January, ASCO held its inaugural Cancer Survivorship Symposium, which brought together the fields of medical oncology and primary care to address the critical need for coordinated care for cancer survivors. Among the presenters at the symposium was Smita Bhatia, MD, MPH, who gave the...
The Role of Occupational and Physical Therapy in Geriatric Oncology
With individuals aged 65 and older accounting for more than 50% of the U.S. population diagnosed with cancer,1 the demand for occupational and physical therapists to treat this population will increase in the years to come. Thus, it is essential for primary care providers to know that the...
Occupational Therapy for Adults With Cancer: An Unmet Need
Adults with cancer are at high risk for functional limitations that would negatively affect their quality of life. Occupational therapy offers a range of supportive services, with the specific goal of helping these patients engage in life as independently as possible. To provide a better...
